---
title: "LBX Pharmacy Chain Joint Stock Company (603883.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603883.SH.md"
symbol: "603883.SH"
name: "LBX Pharmacy Chain Joint Stock Company"
industry: "Drug Retail"
datetime: "2026-05-20T00:04:44.732Z"
locales:
  - [en](https://longbridge.com/en/quote/603883.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603883.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603883.SH.md)
---

# LBX Pharmacy Chain Joint Stock Company (603883.SH)

## Company Overview

LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The company is also involved in wholesale and retail of pharmaceutical products; Chinese medicine research and development; E-commerce; food and department store retail; commodity wholesale; and retail of maternal and infant products.

| Item | Detail |
|------|--------|
| Industry | Drug Retail |
| Exchange | CN Market |
| Website | [www.lbxdrugs.com](https://www.lbxdrugs.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.45)**

**Industry**: Drug Retail

| Metric | Value |
|--------|-------|
| Industry Ranking | 6 / 8 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.13% |  |
| Net Profit YoY | -11.90% |  |
| P/B Ratio | 1.42 |  |
| Dividend Ratio | 1.73% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9651447598.49 |  |
| Revenue | 22261414204.66 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.80% | C |
| Profit Margin | 1.77% | C |
| Gross Margin | 33.51% | C |
| Revenue YoY | 0.13% | C |
| Net Profit YoY | -11.90% | D |
| Total Assets YoY | -5.35% | D |
| Net Assets YoY | -1.58% | D |
| Cash Flow Margin | 809.22% | A |
| OCF YoY | 0.13% | C |
| Turnover | 1.09 | A |
| Gearing Ratio | 63.34% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - LBX Pharmacy Chain Joint Stock Company",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.13%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.42",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.73%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9651447598.49",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "22261414204.66",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.80%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "1.77%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "33.51%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "0.13%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.90%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-5.35%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.58%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "809.22%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "0.13%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "1.09",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "63.34%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 24.66 | 4/8 | 32.29 | 29.97 | 26.89 |
| PB | 1.43 | 3/8 | 2.10 | 1.84 | 1.60 |
| PS (TTM) | 0.44 | 3/8 | 0.64 | 0.56 | 0.49 |
| Dividend Yield | 1.71% | 6/8 | 2.35% | 1.60% | 1.41% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Yifeng Pharmacy (603939.SH) | B | C | B | C | C | B |
| 02 | DSL (603233.SH) | B | C | A | D | B | B |
| 03 | Huaren Health (301408.SZ) | B | B | A | D | A | B |
| 04 | SYPM (301017.SZ) | C | B | A | E | A | B |
| 05 | NO.1 PHARMACY (600833.SH) | C | C | A | C | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-16T16:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 38% |
| Overweight | 5 | 38% |
| Hold | 3 | 23% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.84 |
| Highest Target | 21.58 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603883.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603883.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603883.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603883.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**